首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1736681

2026 年至 2032 年电生理设备市场（按类型、适应症、最终用户和地区划分）

Electrophysiology Devices Market By Type, Indication (Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Tachycardia), End-User, Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

电生理设备市场评估-2026-2032

心血管疾病（尤其是心房颤动）的盛行率不断上升，推动了对电生理设备的需求。因此，心血管疾病（尤其是心房颤动）的盛行率不断上升将推动市场规模的成长，到2024年将达到86亿美元，到2032年将达到193.1亿美元。

老年人口的成长将导致心律不整的发病率上升，进而推动对电生理设备的需求。由于老年人口的成长，预计2026年至2032年期间市场复合年增长率将达到11.73%。

电生理设备市场定义/概述

电生理设备在心律不整和其他电生理异常的诊断和治疗中发挥着至关重要的作用。这些先进的医疗设备旨在测量和分析心臟的电活动，为医疗保健专业人员，尤其是心臟病专家和电生理学家提供重要资讯。这些设备的主要功能是帮助识别异常心律，定位心臟内的心律不整部位，并提供治疗性介入以恢復正常的心臟功能。

电生理学设备涵盖各种工具，例如消融导管、诊断导管、标测系统和3D电解剖标测系统。诊断导管有助于测量心臟的电脉衝，而消融导管则用于将能量输送到特定部位以治疗异常心律。标测系统可即时可视化心臟的电活动，有助于精准诊断和针对性的治疗。

电生理设备的进步彻底改变了心臟护理，使导管消融等微创手术成为可能。这些手术为患者提供了传统开胸心臟外科手术的替代方案，显着缩短了復健时间并改善了治疗效果。随着心臟病日益普遍，对电生理设备的需求预计将持续增长，使其成为现代心血管医学不可或缺的工具。

心导管电气烧灼术治疗的普及是否会加速电生理设备市场的成长？

人们对微创治疗的日益增长的偏好推动了心导管电气烧灼术（电生理设备的主要应用）的采用。根据 2021 年发表在 JAMA Network Open 上的一项研究，2010 年至 2018 年间，美国用于治疗心房颤动的心导管电气烧灼术使用量增加了 51%。这归因于医疗成本的上升和医疗基础设施的改善。医疗保健支出的增加，尤其是在新兴国家，正在推动先进电生理设备的采用。根据世界银行的报告，全球医疗保健支出占 GDP 的比例已从 2010 年的 9.7% 上升到 2019 年的 9.9%，显示对医疗保健技术的投资正在不断扩大。

医院外的应用正在不断扩展。可携式和可穿戴式电生理设备在远端患者监护中的应用日益广泛，这正在创造新的市场机会。根据 Verified Market Research 的研究报告，包括心臟监测设备在内的远端患者监护市场在 2023 年的价值为 417.7 亿美元，预计到 2032 年将达到 1,583.9 亿美元，2026 年至 2032 年的复合年增长率为 20%。此外，电生理技术的不断创新正在扩展这些设备的功能和应用。美国食品药物管理局 (FDA) 在 2021 年核准了132 种新的医疗设备，其中许多属于心血管领域。

电生理学程序和设备的高成本将如何阻碍电生理学设备市场的成长？

电生理学程序和设备价格昂贵，这可能会限制市场成长，尤其是在新兴国家。根据 2021 年发表在《心房颤动杂誌》上的一项研究，在美国，心房颤动心导管电气烧灼术的平均费用在 18,000 美元到 32,000 美元之间，具体取决于所使用的技术和医疗环境。缺乏训练有素的专业人员来执行复杂的电生理学程序，这正在抑制市场扩张。根据心律学会 2022 年的报告，美国祇有约 3,500 名心臟电生理学专家为超过 3.3 亿人口提供服务。这意味着每 94,000 人中只有一名电生理学家，这表明存在严重的人才短缺。

电生理治疗期间可能出现不利事件，这使得一些患者和医疗保健提供者不愿意接受该治疗。 2020 年发表在《欧洲心臟杂誌》上的一项大型研究发现，心导管电气烧灼术治疗的总体併发症发生率为 5.5%，其中 1.7% 的患者出现严重併发症。新型电生理设备的监管途径漫长而复杂，减缓了市场成长。美国 FDA 在 2022 年年度绩效报告中报告称，医疗设备核准(PMA) 申请的平均决策时间为 365 天。这一延长的时间大大延迟了新型电生理技术的市场推广。

The rising incidence of cardiovascular diseases, particularly atrial fibrillation, is driving the demand for electrophysiology devices. Thus, the increasing prevalence of cardiovascular diseases, especially atrial fibrillation surged the growth of market size surpassing USD 8.6 Billion in 2024 to reach the valuation of USD 19.31 Billion by 2032.

Increasing geriatric population increases the incidences of cardiac arrhythmias increases, boosting the demand for electrophysiology devices. Thus, the growing aging population enables the market to grow at a CAGR of 11.73% from 2026 to 2032.

Electrophysiology Devices Market: Definition/ Overview

Electrophysiology devices play a critical role in the diagnosis and treatment of cardiac arrhythmias and other electrical abnormalities of the heart. These sophisticated medical instruments are designed to measure and analyze the heart's electrical activity, providing vital information to healthcare professionals, particularly cardiologists and electrophysiologists. The primary function of these devices is to identify abnormal heart rhythms, pinpoint arrhythmogenic areas within the heart, and assist in delivering therapeutic interventions to restore proper cardiac function.

Electrophysiology devices encompass a wide range of tools, including ablation catheters, diagnostic catheters, mapping systems, and 3D electroanatomical mapping systems. Diagnostic catheters help in measuring electrical impulses in the heart, while ablation catheters are used to deliver energy to specific areas to treat abnormal heart rhythms. Mapping systems provide real-time visualization of the heart's electrical activity, aiding in accurate diagnosis and precise treatment.

The advancement of electrophysiology devices has revolutionized cardiac care, allowing for minimally invasive procedures like catheter-based ablations. These procedures offer patients an alternative to traditional open-heart surgery, significantly reducing recovery time and improving outcomes. As cardiac conditions become more prevalent, the demand for electrophysiology devices is expected to grow, making them indispensable tools in modern cardiovascular medicine.

How does the Increasing Adoption of Catheter Ablation Procedures Surge the Growth of the Electrophysiology Devices Market?

The growing preference for minimally invasive procedures is boosting the adoption of catheter ablation, a key application of electrophysiology devices. A study published in JAMA Network Open in 2021 found that the use of catheter ablation for atrial fibrillation increased by 51% between 2010 and 2018 in the United States. Rising healthcare expenditure and improving healthcare infrastructure. Increased healthcare spending, particularly in emerging economies, is facilitating the adoption of advanced electrophysiology devices. The World Bank reports that global healthcare expenditure as a percentage of GDP increased from 9.7% in 2010 to 9.9% in 2019, indicating a growing investment in healthcare technologies.

Expanding applications in out-of-hospital settings. The increasing use of portable and wearable electrophysiology devices for remote patient monitoring is opening new market opportunities. According to a report by Verified Market Research, the Remote Patient Monitoring Market, which includes cardiac monitoring devices, was valued at USD 41.77 Billion in 2023 and is expected to reach USD 158.39 Billion by 2032, with a growing CAGR of 20% from 2026 to 2032. In addition, the continuous innovations in electrophysiology technologies are expanding the capabilities and applications of these devices. The FDA approved 132 new medical devices in 2021, many of which were in the cardiovascular space.

How Does the High Cost of Electrophysiology Procedures and Devices Impede the Growth of the Electrophysiology Devices Market?

The expensive nature of electrophysiology procedures and devices can limit market growth, especially in developing countries. According to a study published in the Journal of Atrial Fibrillation in 2021, the average cost of catheter ablation for atrial fibrillation in the United States ranged from $18,000 to $32,000, depending on the technology used and the healthcare setting. The lack of trained professionals to perform complex electrophysiology procedures restrains market expansion. A 2022 report by the Heart Rhythm Society stated that there were only about 3,500 board-certified cardiac electrophysiologists in the United States, serving a population of over 330 million. This translates to approximately 1 electrophysiologist per 94,000 people, indicating a significant shortage.

The potential for adverse events during electrophysiology procedures can deter some patients and healthcare providers. A large-scale study published in the European Heart Journal in 2020 found that the overall complication rate for catheter ablation procedures was 5.5%, with 1.7% of patients experiencing major complications. Lengthy and complex regulatory pathways for new electrophysiology devices slow down market growth. The U.S. FDA reported in its 2022 annual performance report that the average time to decision for premarket approval (PMA) applications for medical devices was 365 days. This extended timeline significantly delays the introduction of new electrophysiology technologies to the market.

Category-Wise Acumens

How does the Increasing Heart Failure Incidence in the Growing Aging Population Surge the Growth of the Ablation Catheter Segment?

The ablation catheter segment holds a dominant position in the electrophysiology devices market, driven by its critical role in managing irregular heartbeats that are unresponsive to medication. Ablation catheters are utilized to perform procedures such as radiofrequency (RF) ablation, cryoablation, and pulse field ablation, each offering distinct methods to target and treat abnormal electrical pathways in the heart. The rising incidence of heart failure and arrhythmias, particularly in aging populations. As the elderly are more susceptible to cardiovascular diseases, the demand for effective and reliable electrophysiology treatments, such as ablation catheters, is expected to surge during the forecast period.

The growing awareness of the reliability and success rates of electrophysiology procedures, coupled with continuous advancements in electrophysiology (EP) technology, has significantly boosted the adoption of these devices. Minimally invasive procedures have become increasingly popular, as they offer shorter recovery times, fewer complications, and better patient outcomes compared to traditional open-heart surgeries. Ablation catheters are at the forefront of this shift, as they provide precise, safe, and effective treatment options for a wide range of arrhythmias.

How do the Rising Valvular Heart Disease and High Blood Pressure Cases Foster the Growth of the Atrial Fibrillation (AF) Segment?

The atrial fibrillation (AF) segment is emerging as a dominant in the electrophysiology devices market, driven by the rising incidence of risk factors such as valvular heart disease, high blood pressure, coronary artery disease, and cardiomyopathy, all closely linked to AF. With the global prevalence of AF steadily increasing, there is growing awareness of its severe complications, including stroke, which has heightened the demand for effective treatment options. One of the most impactful treatments is catheter ablation, and its widespread adoption is playing a pivotal role in driving the growth of this segment.

The integration of combination therapies, where electrophysiology devices are used alongside medications to manage various arrhythmias, is further shaping market trends. This multifaceted approach not only improves treatment outcomes but also boosts demand for advanced electrophysiology devices. Additionally, ongoing research into expanding the scope of ablation procedures for arrhythmias beyond AF is expected to create new growth opportunities. As more indications for electrophysiology procedures emerge, niche segments within the market are likely to experience increased investment and innovation. The prominence of AF treatments, particularly catheter ablation, and the continuous advancements in technology ensure that the AF segment will continue to dominate the electrophysiology devices market in the coming years.

How did the High Prevalence of Cardiovascular Diseases and Robust Healthcare Infrastructure Escalate the Growth of the Electrophysiology Devices Market in North America?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is a major driver for the electrophysiology devices market in North America. According to the American Heart Association's 2022 Heart Disease and Stroke Statistics update, an estimated 12.1 million people in the United States are projected to have atrial fibrillation by 2030. This represents a significant increase from the 5.2 million cases reported in 2010, indicating a growing need for electrophysiology devices and procedures.

North America's advanced healthcare system and substantial healthcare spending contribute significantly to the growth of the electrophysiology devices market. The Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending grew 2.7% in 2021 to reach USD 4.3 Trillion, or $12,914 per person. This high level of healthcare expenditure facilitates the adoption of advanced medical technologies, including electrophysiology devices.

The growing preference for minimally invasive electrophysiology procedures is driving market growth in North America. A study published in the Journal of the American College of Cardiology in 2021 reported that the use of catheter ablation for atrial fibrillation in the United States increased by 26% between 2016 and 2020. The study also found that minimally invasive ablation procedures were associated with shorter hospital stays and lower complication rates compared to traditional surgical approaches, further driving their adoption.

How does the High Prevalence of Cardiovascular Diseases and Increasing Life Expectancy Accelerate the Growth of the Electrophysiology Devices Market in Europe?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is driving the demand for electrophysiology devices in Europe. According to the European Society of Cardiology's 2021 Cardiovascular Disease Statistics, over 11 million people in Europe were living with atrial fibrillation in 2020. The report projected this number to increase by 70% by 2030, reaching nearly 17 million cases. This significant growth in atrial fibrillation cases is expected to boost the demand for electrophysiology devices and procedures in the region.

Europe's aging population and rising life expectancy are contributing to the growth of the electrophysiology devices market. Eurostat reported in 2022 that the proportion of people aged 65 years and over in the EU is projected to increase from 20.8% in 2021 to 31.3% by 2100. This demographic shift is likely to increase the incidence of cardiac arrhythmias, driving the demand for electrophysiology devices and procedures.

The European market is seeing a growing adoption of advanced electrophysiology technologies and minimally invasive procedures. A study published in the European Heart Journal in 2023 reported that the number of catheter ablation procedures for atrial fibrillation in Europe increased by 15% between 2019 and 2022. The study also noted that centers performing these procedures grew from 498 to 579 during the same period, indicating a widespread adoption of advanced electrophysiology techniques across the continent.

Competitive Landscape

The Electrophysiology Devices Market is a highly competitive landscape, driven by factors such as technological advancements, increasing prevalence of heart diseases, and growing demand for minimally invasive procedures. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers and patients.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the electrophysiology devices market include:

Siemens AG
Medtronic Plc
Abbot Laboratories
GE Healthcare
Boston Scientific Corporation
Biosense Webster, Inc.
Nihon Kohden Corporation
Biotronik SE & CO. KG
Microport Scientific Corporation
Koninklijke Philips N.V.

Latest Developments:

In March 2021, Beaumont Health announced the launch of a new atrial fibrillation ablation technique to determine if pulsed field ablation may be used to treat individuals with irregular heartbeats.

1 INTRODUCTION OF GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE

5.1 Overview
5.2 Ablation Catheters
5.3 Diagnostic Catheters
5.4 Laboratory Devices
5.5 Mapping System
5.6 Accessories
5.7 Others

6 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY INDICATION

6.1 Overview
6.2 Atrial Fibrillation
6.3 Supraventricular Tachycardia (SVT)
6.4 Ventricular Tachycardia
6.5 Others

7 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY END-USE

7.1 Overview
7.2 Hospitals
7.3 Ambulatory Surgical Centers
7.4 Others

8 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 Siemens AG
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Medtronic Plc
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Abbot Laboratories
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GE Healthcare
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Boston Scientific Corporation
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Biosense Webster, Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Nihon Kohden Corporation
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Biotronik SE & CO. KG
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Koninklijke Philips N.V.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Microport Scientific Corporation
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments